Agile Therapeutics, Inc.: 10-Q filed 2015-11-09

Name: Agile Therapeutics, Inc.: 10-Q filed 2015-11-09
Creator: Agile Therapeutics, Inc.

What Agile Therapeutics, Inc. reported in its quarterly report filed 2015-11-09 (fiscal Q3 2015): 25 published measures, 65 facts as tagged in accession 0001104659-15-077262.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-11-09
Fiscal period: fiscal Q3 2015
Accession: 0001104659-15-077262 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Agile Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-09-30	55,085,584	USD
At 2014-12-31	54,826,226	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-09-30	32,745,950	USD
At 2014-12-31	36,005,947	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-09-30	39,404,313	USD
At 2014-12-31	40,182,141	USD
At 2014-09-30	45,679,880	USD
At 2013-12-31	2,119,646	USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	288,398	USD	273
2014-01-01 to 2014-09-30	42,348	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-09-30	-160,828,102	USD
At 2014-12-31	-134,391,851	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2014-01-01 to 2014-09-30	-3,652,485	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-09-30	12,320,365	USD
At 2014-12-31	12,046,267	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	2,129,172	USD	273
2014-01-01 to 2014-09-30	973,354	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-8,965,201	USD	92
2015-01-01 to 2015-09-30	-23,923,616	USD	273
2014-07-01 to 2014-09-30	-6,048,884	USD	92
2014-01-01 to 2014-09-30	-11,991,221	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-09-30	40,665,012	USD
At 2014-12-31	40,985,916	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	551,713	USD	92
2015-01-01 to 2015-09-30	1,525,136	USD	273
2014-07-01 to 2014-09-30	392,009	USD	92
2014-01-01 to 2014-09-30	1,173,723	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-09-30	6,949,339	USD
At 2014-12-31	8,992,521	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-09-30	4,349,935	USD
At 2014-12-31	2,631,217	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	8,965,201	USD	92
2015-01-01 to 2015-09-30	23,923,616	USD	273
2014-07-01 to 2014-09-30	6,048,884	USD	92
2014-01-01 to 2014-09-30	11,991,221	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	7,162,541	USD	92
2015-01-01 to 2015-09-30	18,708,447	USD	273
2014-07-01 to 2014-09-30	4,602,513	USD	92
2014-01-01 to 2014-09-30	8,387,693	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-09-30	22,292,167	shares
At 2014-12-31	18,634,872	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2015-09-30	193,571,822	USD
At 2014-12-31	170,395,934	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2015-09-30	299,943	USD
At 2014-12-31	285,643	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2015-09-30	18,208	USD
At 2014-12-31	18,208	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-09-30	2,348,157	USD
At 2014-12-31	1,062,113	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-9,411,441	USD	92
2015-01-01 to 2015-09-30	-26,436,250	USD	273
2014-07-01 to 2014-09-30	-6,353,362	USD	92
2014-01-01 to 2014-09-30	-12,884,955	USD	273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	-9,411,441	USD	92
2015-01-01 to 2015-09-30	-26,436,250	USD	273
2014-07-01 to 2014-09-30	-6,353,362	USD	92
2014-01-01 to 2014-09-30	-9,232,470	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	1,802,660	USD	92
2015-01-01 to 2015-09-30	5,215,169	USD	273
2014-07-01 to 2014-09-30	1,446,371	USD	92
2014-01-01 to 2014-09-30	3,603,528	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	14,300	USD	273
2014-01-01 to 2014-09-30	7,730	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2015-01-01 to 2015-09-30	19,330,613	USD	273
2014-01-01 to 2014-09-30	49,743,641	USD	273

Inspect the source

Entity: Agile Therapeutics, Inc. / CIK 0001261249
Captured: 2026-09-22 19:42 UTC
SEC response SHA-256: dfa60388e3d618cfe1a780836e21d55d8bef6ac848684cf8fd7d6373390ae6f6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001261249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))